Aptargroup Stock Price, News & Analysis

AptarGroup (NYSE: ATR) has been recognized as one of America's Most Responsible Companies 2025 by Newsweek, ranking 71st out of 600 U.S. companies. This marks the sixth consecutive year of this achievement.

The company, which specializes in drug and consumer product dosing, dispensing and protection technologies, has been acknowledged for its sustainability initiatives, including sourcing renewable energy, certifying sites as landfill-free, and developing more sustainable products that are recyclable, reusable, and refillable.

Aptar has also received recognition from Forbes as a World's Top Companies for Women and from TIME as one of the World's Most Sustainable Companies. As an active member of the Ellen MacArthur Foundation and the World Business Council for Sustainable Development, Aptar is working towards advancing circular economy initiatives.

The Newsweek ranking, conducted in partnership with Statista, evaluated the top 2,000 largest public U.S. companies based on ESG criteria and a perception study of 26,000 individuals, considering factors such as emissions, energy use, board diversity, and transparency.

AptarGroup (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has announced its 2025 quarterly conference call schedule. The company will host four earnings calls throughout the year, each beginning at 8:00 a.m. Central Time.

The schedule is as follows:

• Q4 and Annual 2024 Results: Press release on February 6, call on February 7
• Q1 2025 Results: Press release on May 1, call on May 2
• Q2 2025 Results: Press release on July 31, call on August 1
• Q3 2025 Results: Press release on October 30, call on October 31

Press releases will be issued after NYSE trading closes on the specified dates. Interested parties can access live webcasts through investors.aptar.com, where call replays will also be available. Each conference call is expected to last approximately one hour.

AptarGroup (NYSE: ATR), a leader in drug and consumer product dosing, dispensing and protection technologies, has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. Stephan Tanda, President and CEO, will deliver a presentation at 12:45 p.m. EST. Executive Vice President and CFO Vanessa Kanu and Aptar Pharma President Gael Touya will also be in attendance. The presentation materials will be accessible to investors through the company's website at www.aptar.com.

AptarGroup (NYSE: ATR) has been recognized among Forbes' 'World's Top Companies for Women 2024', ranking 41st out of 400 companies. This marks the fourth consecutive year of recognition for Aptar, highlighting their commitment to Inclusion, Equity and Belonging (IE&B). The company demonstrates strong female representation with 50% women on their Board of Directors and 37% women on their executive committee.

The ranking, conducted in partnership with Statista, evaluated companies across three categories: employer brand, public opinion, and leadership. The assessment involved surveying approximately 100,000 women from multinational corporations across 37 countries, focusing on companies operating in at least two continental regions.

AptarGroup (NYSE:ATR) reported strong Q3 2024 results with a 2% increase in both reported and core sales to $909 million. Net income rose 19% to $100 million, with earnings per share up 17% to $1.48. The Pharma segment led growth with 8% reported sales increase, while Closures grew 3% and Beauty declined 7%. The company achieved an adjusted EBITDA of $208 million, delivering a 23% margin. For Q4 2024, Aptar expects earnings per share between $1.22 and $1.30, targeting double-digit adjusted EPS growth for the full year.

AptarGroup, Inc. (NYSE: ATR) has been awarded a $4.8 million, five-year contract from the U.S. Federal Government to advance development of its ActivShield™ technology. This innovative solution sterilizes medical devices and instruments without a power source, making it suitable for rural areas, military settings, and healthcare facilities with sterilization capabilities.

ActivShield™ uses Aptar CSP Technologies' 3-Phase Activ-Polymer™ platform and emits controlled chlorine dioxide gas for sterilization. It offers advantages over conventional methods, including portability, no infrastructure requirements, and absence of health risks associated with Ethylene Oxide (EtO). The technology can be custom-engineered, is stable, compact, and manufactured in the United States.

This advancement could significantly reduce infection risks in remote or emergency response settings and decrease reliance on expensive and unsafe sterilization techniques. For the military, it can provide access to sterilized instruments in far-forward environments during critical pre-hospitalization periods.

AptarGroup, Inc. (NYSE: ATR) has announced a new $500 million share repurchase authorization, replacing all previous authorizations. The company may repurchase shares through various methods, subject to market conditions. Additionally, Aptar declared a quarterly cash dividend of $0.45 per share, payable on November 14, 2024, to stockholders of record as of October 24, 2024.

CEO Stephan Tanda highlighted Aptar's balanced approach to capital allocation, focusing on returning capital to shareholders and reinvesting in the business. Over the past five years, Aptar has returned more than $780 million to stockholders through dividends and share repurchases. The company maintains flexibility in the timing and amount of share repurchases based on various factors.

AptarGroup, Inc. (NYSE: ATR) announced that its N-Sorb nitrosamine mitigation solution has been accepted into the U.S. FDA's Emerging Technology Program (ETP). N-Sorb uses Aptar CSP Technologies' 3-Phase Activ-Polymer™ platform to address N-nitrosamine impurities in pharmaceuticals, which are classified as probable human carcinogens.

The technology can be integrated into blister packaging or container closure systems, reacting with nitrosamine precursors and scavenging impurities. This active packaging intervention could eliminate the need for drug reformulation, supporting compliance with FDA and EMA regulations. The FDA's acceptance of N-Sorb into the ETP is seen as a significant step, as the program is highly selective and reserved for promising healthcare solutions.

AptarGroup, Inc. (NYSE: ATR) announced that its Unidose Liquid System is the delivery system approved for neffy® (epinephrine nasal spray), the first FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis. This marks the first worldwide regulatory approval for nasally-delivered epinephrine. Aptar's Unidose is a single-use, ready-to-use, one-step nasal delivery system that administers neffy during severe allergic reactions. The system's design promotes ease of use and adherence for patients and caregivers. Aptar Pharma Services supported the development process, helping to accelerate approval for this novel Combination Product submission.